

Add claims 183-191 which follow.

- Claim 183: An isolated tumor rejection antigen precursor protein, wherein said protein is encoded by a nucleic acid molecule, the complementary sequence of which hybridizes to SEQ ID NO: 8 at 0.1XSSC, 0.1% SDS.
- Claim 184: The isolated tumor rejection antigen precursor protein of claim 183, the amino acid sequence of which comprises the amino acid sequence set forth in SEQ ID NO: 26.
- Claim 185: The isolated tumor rejection antigen precursor protein of claim 183, wherein said protein is a human protein.
- Claim 186: Composition comprising the isolated tumor rejection antigen precursor protein of claim 183, and a pharmaceutically appropriate ingredient.
- Claim 187: Composition comprising the isolated tumor rejection antigen precursor protein of claim 184, and a pharmaceutically appropriate ingredient.
- Claim 188: Composition comprising the isolated tumor rejection antigen precursor protein of claim 185, and a pharmaceutically appropriate ingredient.
- Claim 189: The composition of claim 186, in the form of a vaccine.
- Claim 190: The composition of claim 187, in the form of a vaccine.
- Claim 191: The composition of claim 188, in the form of a vaccine.

**REMARKS**

Entry of the amendment is requested. The amendment is in accordance with 37 CFR § 1.121(h).

With respect to point 2 of the action, applicants again point out that when they raised the issues regarding PTO errors, two of the three PTO staff members who were present at the interview